2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells

Biochemical and Biophysical Research Communications

Volumn 431, Issue 4, 2013, Pages 746-752

  Lee, Sang Bum ^a   Gong, Young Dae ^b   Park, Young In ^a   Dong, Mi Sook ^a  

^a Korea University   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

NSCLC; Radiosensitizer; Wnt catenin signal pathway inhibitor

Indexed keywords

BETA CATENIN; CYCLIN D1; DICKKOPF 1 PROTEIN; GDK 100017; LYMPHOID ENHANCER FACTOR 1; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; WNT2 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DOSE RESPONSE; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN D1; HUMANS; LUNG NEOPLASMS; QUINOXALINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RESPIRATORY MUCOSA; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84875249240     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.038     Document Type: Article

References (22)

1. Moon R.T., Brown J.D., Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends in genetics: TIG 1997, 13:157-162.
2. Chesire D.R., Ewing C.M., Sauvageot J., Bova G.S., Isaacs W.B. Detection and analysis of beta-catenin mutations in prostate cancer. The Prostate 2000, 45:323-334.
3. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
4. Xu W.L., Wang Q., Du M., Zhao Y.H., Sun X.R., Sun W.G., Chen B.Q. Growth inhibition effect of beta-catenin small interfering RNA-mediated gene silencing on human colon carcinoma HT-29 cells. Cancer biotherapy & radiopharmaceuticals 2010, 25:529-537.
5. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
6. Watanabe K., Dai X. Winning WNT: race to Wnt signaling inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5929-5930.
7. Lundin A., Driscoll B. Lung cancer stem cells: progress and prospects. Cancer letters 2012, pii: S0304-3835(12)00485-5.
8. Mazieres J., He B., You L., Xu Z., Jablons D.M. Wnt signaling in lung cancer. Cancer letters 2005, 222:1-10.
9. You L., He B., Xu Z., Uematsu K., Mazieres J., Mikami I., Reguart N., Moody T.W., Kitajewski J., McCormick F., Jablons D.M. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004, 23:6170-6174.
10. Nambiar D., Rajamani P., Singh R.P. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutation research 2011, 728:139-157.
11. Russo A.L., Kwon H.C., Burgan W.E., Carter D., Beam K., Weizheng X., Zhang J., Slusher B.S., Chakravarti A., Tofilon P.J., Camphausen K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:607-612.
12. Lee S.B., Park Y.I., Dong M.S., Gong Y.D. Identification of 2,3,6-trisubstituted quinoxaline derivatives as a Wnt2/beta-catenin pathway inhibitor in non-small-cell lung cancer cell lines. Bioorganic & medicinal chemistry letters 2010, 20:5900-5904.
13. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., Hild M., Shi X., Wilson C.J., Mickanin C., Myer V., Fazal A., Tomlinson R., Serluca F., Shao W., Cheng H., Shultz M., Rau C., Schirle M., Schlegl J., Ghidelli S., Fawell S., Lu C., Curtis D., Kirschner M.W., Lengauer C., Finan P.M., Tallarico J.A., Bouwmeester T., Porter J.A., Bauer A., Cong F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
14. Gonsalves F.C., Klein K., Carson B.B., Katz S., Ekas L.A., Evans S., Nagourney R., Cardozo T., Brown A.M., DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:5954-5963.
15. Yao H., Ashihara E., Strovel J.W., Nakagawa Y., Kuroda J., Nagao R., Tanaka R., Yokota A., Takeuchi M., Hayashi Y., Shimazaki C., Taniwaki M., Strand K., Padia J., Hirai H., Kimura S., Maekawa T. AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer Journal 2011, 1:e43.
16. Emami K.H., Nguyen C., Ma H., Kim D.H., Jeong K.W., Eguchi M., Moon R.T., Teo J.L., Kim H.Y., Moon S.H., Ha J.R., Kahn M. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:12682-12687.
17. Konigshoff M., Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal?. American Journal of Respiratory Cell and Molecular Biology 2010, 42:21-31.
18. Zhang F., Zhang T., Gu Z.P., Zhou Y.A., Han Y., Li X.F., Wang X.P., Cheng Q.S., Mei Q.B. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. Journal of Radiation Research 2008, 49:541-548.
19. Fokas E., Yoshimura M., Prevo R., Higgins G., Hackl W., Maira S.M., Bernhard E.J., McKenna W.G., Muschel R.J. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation Oncology 2012, 7:48.
20. Prevo R., Deutsch E., Sampson O., Diplexcito J., Cengel K., Harper J., O'Neill P., McKenna W.G., Patel S., Bernhard E.J. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Research 2008, 68:5915-5923.
21. Seeliger H., Guba M., Kleespies A., Jauch K.W., Bruns C.J. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Reviews 2007, 26:611-621.
22. Yang D., Tan M., Wang G., Sun Y. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLoS One 2012, 7:e34079.